Latest News on Cannabis Science (OTC:CBIS)
Cannabis Science Releases Cannabinoid-Formulated Capsule Product Line in California; Initial Capsule Formulations Released Are CBD, Indica, and Sativa
COLORADO SPRINGS, CO--(Marketwired - Nov 30, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based formulation, announces the launch of their cannabinoid-formulated capsule product line. The initial capsule formulations released are CBD, Indica, and Sativa; each of the three types of caps will be available in 25mg, 50mg, and 100mg doses and will be provided in two-dose packs with more size options to be made available in the near future.
"We are very excited to get our next line of Cannabis Science Brand Products on the market. The Capsules are important because of the popularity and ease of the delivery mechanism. The Company reps have already begun distributing to a number of dispensaries throughout California. They anticipate the Caps to be in a much larger number of dispensaries, and look forward to being able to line the shelves with a full lineup of Cannabis Science Brand Health-Related Products. Debuting the Caps at the Emerald Cup will be very interesting for us, with this being our first actual product contest," stated Cannabis Science, Inc. President & CEO, Co-Founder, Raymond C. Dabney. Read Full Press Release
Cannabis Science, Inc. Retains i-Business Management, LLC for Investor and Public Relations, Focusing on Corporate and Product Branding
COLORADO SPRINGS, CO--(Marketwired - Nov 19, 2015) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, has retained i-Business Management, LLC for investor and public relations. The Company expects this newly-formed relationship to create more effective communications with shareholders, increase brand and product recognition, and improve social media reach. Click on Title to read full press release.
May 27, 2015 - CANNABIS SCIENCE BRINGS CS-TATI-1 TO THE FDA WITH HISTORIC COLLABORATIVE DRUG DEVELOPMENT DEAL WITH IGXBIO AND ITS GENEPRO®, A DNA-BASED IMMUNOTHERAPEUTIC THAT RECENTLY RECEIVED FDA APPROVAL TO ENTER INTO HUMAN TRIALS
COLORADO SPRINGS, Colo., May 27, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabis-based medicine and related consulting, has announced a Historic Collaborative Drug Development deal with IGXBio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates. Click on Title to read full press release.